Abstract:Abstract Background:CA199, CEA and CA125 were the most widely used tumor markers in pancreatic cancer. However, the studies associated with the relationship between the three markers and pancreatic cancer were limited. This study aimed to explore the correlation between baseline serum CA199, CEA, CA125 levels and clinical characteristics in pancreatic cancer. Methods:278 patients with advanced pancreatic cancer received first-line chemotherapy treatments enrolled in this research. Correlated analysis between tumor markers and disease characteristics was performed by Pearson’s Chi-squared test or Fisher exact test. We used Pearson’s correlation test to investigate the relationship between tumor markers and peripheral blood parameters. Univariate analysis was estimated by Kaplan-Meier method and compared using the log-rank test. Multivariate analysis and HR calculation was determined by the Cox regression model. Results: Baseline CA199, CEA, and CA125 both positively associated with the primary tumor site (p=0.007; p=0.012; p=0.003, respectively);liver metastasis (p=0.001; p=0.001; p=0.028, respectively); number of organ metastasis (p=0.001; p=0.008;p=0.042, respectively); baseline WBC levels (p<0.001; p<0.001; p<0.001, respectively), LDH levels (p<0.001; p=0.004; p<0.001, respectively). And CA199 also correlated with years of smoking(p=0.024); diabetes and year of diabetes (p=0.012; p=0.012); baseline glycemic levels (p=0.004). CA199 and CA125 levels had the relationship with baseline neutrophil counts (p<0.001; p<0.001, respectively). Years of smoking, baseline neutrophil counts, LDH levels, CA199 levels and CA125 levels were independent prognostic factors. Conclusion: Combinations of the four factors were also correlated with survival. It’s concluded that CA199, CEA, CA125 correlated with multi-factors of clinical factors. And combinations of baseline neutrophil counts, LDH levels, CA199 levels and CA125 levels were also prognostic factor.

Elevated Serum CD26 Level is Associated with Metastasis and Post-Operation Survival in Pancreatic Cancer Patients

Cd26 As A Promising Biomarker For Predicting Prognosis In Patients With Pancreatic Tumors

Suppression of CD26 Inhibits Growth and Metastasis of Pancreatic Cancer

Down-expression of CD36 in Pancreatic Adenocarcinoma and Its Correlation with Clinicopathological Features and Prognosis.

Clinical Significance of the Serum-Soluble Intercellular Adhesion Molecule-1 in Patients Undergoing Radical Resection of Lung Cancer

Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy

Prognostic Value of Programmed Cell Death Protein 1 Expression on CD8+ T Lymphocytes in Pancreatic Cancer

Plasma Soluble Cluster of Differentiation 147 Levels Are Increased in Breast Cancer Patients and Associated with Lymph Node Metastasis and Chemoresistance.

Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer

Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients

Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer

Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer

Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

Serum CA125 is a Novel Predictive Marker for Pancreatic Cancer Metastasis and Correlates with the Metastasis-Associated Burden.

Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy

Cd26/Dipeptidyl Peptidase Iv Contributes to Tumor Metastasis in Human Lung Adenocarcinoma

Is sCD163 a Clinical Significant Prognostic Value in Cancers? A Systematic Review and Meta-Analysis

Clinical Implications of Systemic Inflammatory Response Markers As Independent Prognostic Factors for Advanced Pancreatic Cancer

O11 Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) is an Important Clinical and Prognostic Indicator in Pancreatic Cancer

The Correlation Analysis of Baseline Serum CA199, CEA and CA125 in Patients with Advanced Pancreatic Cancer

Serum sCD44s and sCD44v6 levels in breast cancer patients